Log In
BCIQ
Print this Print this
 

SynCon DNA HBV vaccine (INO-1800)

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynthetic DNA vaccine encoding a recombinant consensus plasmid from genotype A through E of the hepatitis B core antigen (HBcAg)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat HBV infection
Regulatory Designation
PartnerRoche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$422.5M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/16/2013

$422.5M

Undisclosed

Undisclosed

Get a free BioCentury trial today